Trial Profile

Randomized phase II trial of autologous vaccines consisting of adjuvant GM-CSF plus proliferating tumor cells versus GM-CSF plus dendritic cells loaded with proliferating tumor cells in patients with metastatic melanoma (MAC-VAC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Apr 2020 According to an AiVita Biomedical media release, results from this study were published in the Journal of Translational Medicine.
04 Jun 2019 Results assessing survival for melanoma patients who were treated with patient specific vaccines by using data from two phase II studies presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
03 Jun 2019 Pooled data from this and other trial (NCT00436930) were presented in an AiVita Biomedical Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com